(Vienna, 25 June 2025) The scientist, physician and globally recognised expert in haematology, oncology, immunotherapy and stem cell transplantation, co-founder of the Mainz-based company BioNTech and member of the University Council of MedUni Vienna, Christoph Huber, has been awarded the German Cancer Aid Prize in recognition of his pioneering work, initiatives and contributions to cancer immunotherapy.
"With his pioneering research in cancer immunotherapy, including the development of recombinant defence hormones (cytokines), the characterisation of tumour-specific antigens, cell therapies and various tumour vaccine formats, Professor Christoph Huber has made a significant contribution to cancer research and treatment. Like few others, he recognised the enormous potential of immunological approaches at an early stage and is considered a true pioneer in this field," said Anne-Sophie Mutter, President of German Cancer Aid, in praise of the award winner.
Christoph Huber, a member of the University Council of MedUni Vienna, was Professor of Haematology/Oncology at Johannes Gutenberg University Mainz and played a key role in transferring academic research into clinical practice and concrete healthcare solutions. As a physician, researcher, leader and advisor to numerous research funding organisations, universities, companies, investors and governments, he has contributed significantly to the advancement of cancer research and its clinical application. During his scientific career, Professor Christoph Huber founded and led numerous research projects, including special research areas, centres of excellence and cutting-edge technology clusters.